Press Releases
Press Releases
-
Rezolute Added to Russell Microcap® Index
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
-
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
-
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
-
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
-
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
-
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
-
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
-
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
-
Rezolute to Participate in Upcoming Investor Conferences in March
-
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
-
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
-
Rezolute Announces Change of Transfer Agent
-
FDA Clears Rezolute’s IND Application for RZ402
-
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Rezolute Announces Uplisting to the Nasdaq Capital Market
-
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
-
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
-
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
-
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
-
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
-
Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
-
Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
-
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
-
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
-
Rezolute to Present at BIO CEO & Investor Conference 2020
-
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
-
Rezolute Management to Present at 2020 Biotech Showcase Conference
-
Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
-
Rezolute Management to Present at 2019 BIO Investor Forum Conference
-
Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
-
Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
-
Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
-
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
-
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
-
Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
-
Rezolute, Inc. Announces Close of Convertible Note Financing
-
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
-
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
-
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
-
AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
-
AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
-
AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
-
AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
-
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
-
AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
-
AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
-
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
-
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
-
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
-
AntriaBio Announces $12 Million Private Placement
-
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
-
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
-
AntriaBio Announces First Close of Private Placement Transaction
-
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
-
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
-
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
-
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
-
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
-
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
-
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
-
AntriaBio Announces $7 Million Private Placement
-
AntriaBio Extinguishes $44 Million Contingent Liability
-
AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors
-
AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
-
AntriaBio, Inc. to Present at the Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014
-
AntriaBio, Inc. Establishes Manufacturing and Laboratory Facility in Colorado
-
AntriaBio, Inc. Announces 1-for-6 Reverse Stock Split
-
AntriaBio, Inc. Launches Digital Corporate Communication Channels
-
AntriaBio Announces Formation of Scientific Advisory Board
-
AntriaBio, Inc. Announces $10 Million Private Placement
-
AntriaBio, Inc. to Present at 26th Annual ROTH Conference
-
AntriaBio to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
-
AntriaBio Announces Closing of Bridge Financing
-
AntriaBio Granted European Patent Allowance for Method of Preparing Site-Specific Protein Conjugates
-
AntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement
-
AntriaBio Appoints Two Industry Leaders to Its Management Team
-
AntriaBio Announces Stock Ticker Symbol Change to ANTB
-
UPDATE: AntriaBio Completes Merger and Elects Board of Directors
-
AntriaBio Acquires Assets of PR Pharmaceuticals and Announces Intent to Merge With a Public Company
